These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38962387)

  • 21. Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d'Aosta Region, Italy, in the 2023-2024 Epidemic Season.
    Consolati A; Farinelli M; Serravalle P; Rollandin C; Apprato L; Esposito S; Bongiorno S
    Vaccines (Basel); 2024 May; 12(5):. PubMed ID: 38793800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials.
    Mankad VS; Leach A; Chang Y; Wählby Hamrén U; Kiazand A; Kubiak RJ; Takas T; Villafana T; Shroff M
    Pathogens; 2024 Jun; 13(6):. PubMed ID: 38921800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus.
    Debessai H; Jones JM; Meaney-Delman D; Rasmussen SA
    Obstet Gynecol; 2024 Mar; 143(3):e54-e62. PubMed ID: 38061043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis.
    Turalde-Mapili MWR; Mapili JAL; Turalde CWR; Pagcatipunan MR
    Front Pediatr; 2023; 11():1132740. PubMed ID: 37082704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg.
    Ernst C; Bejko D; Gaasch L; Hannelas E; Kahn I; Pierron C; Del Lero N; Schalbar C; Do Carmo E; Kohnen M; Andlauer E; Hublart P; Masi S; de la Fuente Garcia I; Vergison A; Mossong J
    Euro Surveill; 2024 Jan; 29(4):. PubMed ID: 38275017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season.
    Dagan R; Hammitt LL; Seoane Nuñez B; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Chang Y; Currie A; Grenham A; Shroff M; Takas T; Mankad VS; Leach A; Villafana T
    J Pediatric Infect Dis Soc; 2024 Feb; 13(2):144-147. PubMed ID: 38219024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024.
    López-Lacort M; Muñoz-Quiles C; Mira-Iglesias A; López-Labrador FX; Mengual-Chuliá B; Fernández-García C; Carballido-Fernández M; Pineda-Caplliure A; Mollar-Maseres J; Shalabi Benavent M; Sanz-Herrero F; Zornoza-Moreno M; Pérez-Martín JJ; Alfayate-Miguelez S; Pérez Crespo R; Bastida Sánchez E; Menasalvas-Ruiz AI; Téllez-González MC; Esquiva Soto S; Del Toro Saravia C; Sanz-Muñoz I; Eiros JM; Matías Del Pozo V; Toquero-Asensi M; Pastor-Villalba E; Lluch-Rodrigo JA; Díez-Domingo J; Orrico-Sánchez A
    Euro Surveill; 2024 Feb; 29(6):. PubMed ID: 38333937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
    Sun M; Lai H; Na F; Li S; Qiu X; Tian J; Zhang Z; Ge L
    JAMA Netw Open; 2023 Feb; 6(2):e230023. PubMed ID: 36800182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Will nirsevimab be the holy grail for prevention of respiratory syncytial virus lower respiratory tract infections in infants?
    Homaira N
    Transl Pediatr; 2024 Mar; 13(3):525-529. PubMed ID: 38590379
    [No Abstract]   [Full Text] [Related]  

  • 30. Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants.
    Wilkins D; Yuan Y; Chang Y; Aksyuk AA; Núñez BS; Wählby-Hamrén U; Zhang T; Abram ME; Leach A; Villafana T; Esser MT
    Nat Med; 2023 May; 29(5):1172-1179. PubMed ID: 37095249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Respiratory Syncytial Virus (RSV) Burden in Infants in the Kingdom of Saudi Arabia and the Impact of All-Infant RSV Protection: A Modeling Study.
    Alharbi A; Yousef A; Zubani A; Alzahrani M; Al-Hindi M; Alharbi S; Alahmadi T; Alabdulkarim H; Kazmierska P; Beuvelet M
    Adv Ther; 2024 Apr; 41(4):1419-1435. PubMed ID: 38356106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model.
    Kieffer A; Beuvelet M; Sardesai A; Musci R; Milev S; Roiz J; Lee JKH
    J Infect Dis; 2022 Aug; 226(Suppl 2):S282-S292. PubMed ID: 35968866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parental knowledge on the respiratory syncytial virus before the nirsevimab immunization program: Attitudes toward immunization in an autonomous community of Spain.
    Zornoza Moreno M; Pérez Martín JJ; Moreno MCG; Abellán MPR
    Hum Vaccin Immunother; 2024 Dec; 20(1):2357439. PubMed ID: 38857859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials.
    Ahani B; Tuffy KM; Aksyuk AA; Wilkins D; Abram ME; Dagan R; Domachowske JB; Guest JD; Ji H; Kushnir A; Leach A; Madhi SA; Mankad VS; Simões EAF; Sparklin B; Speer SD; Stanley AM; Tabor DE; Hamrén UW; Kelly EJ; Villafana T
    Nat Commun; 2023 Jul; 14(1):4347. PubMed ID: 37468530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Balanced on the Biggest Wave: Nirsevimab for Newborns.
    McPherson C; Lockowitz CR; Newland JG
    Neonatal Netw; 2024 Apr; 43(2):105-115. PubMed ID: 38599778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential Impact of Nirsevimab on RSV Transmission and Medically Attended Lower Respiratory Tract Illness Caused by RSV: A Disease Transmission Model.
    Voirin N; Virlogeux V; Demont C; Kieffer A
    Infect Dis Ther; 2022 Feb; 11(1):277-292. PubMed ID: 34813073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023-January 2024.
    Paireau J; Durand C; Raimbault S; Cazaubon J; Mortamet G; Viriot D; Milesi C; Daudens-Vaysse E; Ploin D; Tessier S; Vanel N; Chappert JL; Levieux K; Ollivier R; Daoudi J; Coignard B; Leteurtre S; Parent-du-Châtelet I; Vaux S
    Influenza Other Respir Viruses; 2024 Jun; 18(6):e13311. PubMed ID: 38840301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Respiratory Syncytial Virus Infections in Neonates: A Persisting Problem.
    Singh S; Maheshwari A; Namazova I; Benjamin JT; Wang Y
    Newborn (Clarksville); 2023; 2(3):222-234. PubMed ID: 38348152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralizing activity of anti-respiratory syncytial virus monoclonal antibody produced in
    Pisuttinusart N; Rattanapisit K; Srisaowakarn C; Thitithanyanont A; Strasser R; Shanmugaraj B; Phoolcharoen W
    Hum Vaccin Immunother; 2024 Dec; 20(1):2327142. PubMed ID: 38508690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants.
    Jorgensen SCJ
    J Antimicrob Chemother; 2023 May; 78(5):1143-1149. PubMed ID: 36922390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.